IOL Chemicals and Pharmaceuticals enterprise value

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5,302————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
68.968.981.510.64.0
13213211732.879.6
5,365————
63.163.135.622.275.7
₹182.77————
1,9311,9311,8051,6441,587
6.8%6.8%6.5%2.0%5.0%
0.02×————
2.13×————
17.29×————
23.48×————
129.81×————
Reference items — trailing FY values
2,5242,3192,0792,1332,217
310269202231226
229189130168180
—214179290122
41.341.3−34.915.9−89.6
—37.6−38.911.7−93.9
—173214274212
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

IOLCP₹180.62

IOL Chemicals and Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMOREPENLABFDCINNOVACAPORCHPHARMASENORESSANOFIGUJTHEMRPGLIFEMcap ₹5,302 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————5,302.1
- Cash, Equiv & ST Investments4.010.681.568.968.9
+ Total Debt79.632.8117.0132.0132.0
Enterprise Value————5,365.2
Net Debt (memo)75.722.235.663.163.1
EV per Share————182.77
Total Capital1,587.41,644.31,804.71,930.61,930.6
Total Debt/Total Capital5.021.996.496.846.84
Total Debt/EV————0.02
EV/Sales————2.13
EV/EBITDA————17.29
EV/EBIT————23.48
EV/Free Cash Flow————129.81
Reference Items — Trailing FY Values
Sales2,217.12,132.82,079.22,319.12,523.6
EBITDA225.7230.6202.3269.0310.3
EBIT179.5167.7130.3188.7228.5
Operating Cash Flow122.3290.1178.6214.3—
Free Cash Flow-89.615.9-34.941.341.3
FCFF (free cash flow to the firm)-93.911.7-38.937.6—
Capital Expenditure211.8274.2213.6173.0—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.